Replies to post #244998 on Biotech Values

[DewDiligence]

Reminder_of_why_Daxxify_for CD is_a_big_deal_for_patients:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155833598

p.s. The stock is +9%/AH.

[DewDiligence]

RVNC manufacturing expansion for CD launch…

RVNC submitted a PAS* to the FDA in Oct 2022 to enable manufacturing of Daxxify at Ajinomoto’s site in San Diego (https://investors.revance.com/news-releases/news-release-details/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce ; https://investors.revance.com/news-releases/news-release-details/revance-reports-third-quarter-2022-financial-results-provides [see the sixth bullet under the heading, “Third Quarter Highlights and Subsequent Updates”].

FDA approval of the manufacturing PAS should come before—or concurrently with—FDA approval of Daxxify for cervical dystonia, enabling RVNC to have sufficient production volume for the CD launch.

*Prior-Approval Supplement.